Alnylam Pharmaceuticals
ALNY
#638
Rank
โ‚น2.686 T
Marketcap
โ‚น20,707
Share price
-0.59%
Change (1 day)
33.90%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -โ‚น15.6 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น2.09 Billion. In 2023 the company made an earning of -โ‚น26.51 Billion, an increase over its 2022 earnings that were of -โ‚น82.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚น15.6 Billion-41.17%
2023 -โ‚น26.51 Billion-67.84%
2022 -โ‚น82.42 Billion36.93%
2021 -โ‚น60.19 Billion-8.04%
2020 -โ‚น65.45 Billion-15.66%
2019 -โ‚น77.6 Billion12.23%
2018 -โ‚น69.15 Billion62.91%
2017 -โ‚น42.45 Billion17.78%
2016 -โ‚น36.04 Billion43.44%
2015 -โ‚น25.13 Billion60.69%
2014 -โ‚น15.64 Billion98.2%
2013 -โ‚น7.89 Billion
2011 -โ‚น4.66 Billion27.48%
2010 -โ‚น3.65 Billion-10.92%
2009 -โ‚น4.1 Billion95.77%
2008 -โ‚น2.1 Billion
2006 -โ‚น3.36 Billion-9.13%
2005 -โ‚น3.69 Billion34.74%
2004 -โ‚น2.74 Billion36.79%
2003 -โ‚น2.01 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚น49.24 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น421.75 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น10.98 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น10.01 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น3.52 Billion-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.080 T-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น628.70 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น35.64 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel